What Hera BioLabs’ absorption into Demeetra reveals about IP bottlenecks in gene editing R&D
Demeetra’s acquisition of Hera BioLabs consolidates Super piggyBac IP. Find out how this could reshape gene therapy tools and licensing frameworks.
Medical Devices & Diagnostics
Pharma & Biotech
Sinorda bets on bispecifics with WuXi Biologics for IBD and autoimmune expansion
WuXi Biologics and Sinorda Biomedicine have entered into a strategic collaboration to advance the development and clinical manufacturing of SND006, a novel bispecific antibody targeting inflammatory bowel disease and other autoimmune conditions. The agreement will see Sinorda Biomedicine utilize WuXi Biologics’ CRDMO capabilities to support preclinical development, IND-enabling activities, and global clinical supply for SND006,
Pharma & Biotech
Parkinson’s disease research shifts toward proteoform-level resolution with Nautilus Biotechnology’s platform
Find out how proteoform-level proteomics could transform Parkinson’s biomarker research and reshape future clinical trials.
Pharma & Biotech
Sixty Degrees Pharmaceuticals bets on purification science to unlock castanospermine commercialization
Find out how Sixty Degrees Pharmaceuticals is repositioning castanospermine through a botanical pathway and what regulatory and manufacturing risks still remain.
Pharma & Biotech
Johnson & Johnson expands DARZALEX FASPRO label with new D-VRd approval in newly diagnosed myeloma
Find out how DARZALEX FASPRO’s FDA approval for transplant-ineligible myeloma patients could shift frontline treatment standards.
Pharma & Biotech
Why Boehringer’s TL1A/IL23 bispecific bet could reshape IBD drug development
Find out why Boehringer is betting big on Simcere’s bispecific SIM0709 to challenge the IBD treatment ceiling.
Pharma & Biotech
Will TETRAPHARM’s TPC-026 unlock the chronic-care gap in metabolic disorders?
Can TPC-026 fill the gap after GLP-1s? Find out how TETRAPHARM’s novel compound could reshape long-term metabolic care.
Pharma & Biotech
What sets Hanmi’s GLP-1 strategy apart as efpeglenatide heads into Latin America
Hanmi taps Sanfer to launch GLP-1 drug efpeglenatide in Mexico. Find out what this deal reveals about Latin America’s obesity drug market strategy.
Medical Devices & Diagnostics
Could Fujirebio’s pTau 217 CSF assay become a new standard in Alzheimer’s research?
Find out how Fujirebio’s new Lumipulse pTau 217 CSF assay could shape the future of Alzheimer’s biomarker research and platform-based diagnostics.
Medical Devices & Diagnostics
What the USDTL–CourtFact deal reveals about tech’s role in court-managed care
Find out how USDTL’s integration with CourtFact could reshape digital drug testing workflows for justice-involved programs.